NXD 9062, a new drug designed to stop cell damage similar to that seen in the brains of patients with Alzheimer's disease, has produced encouraging results in preclinical laboratory studies, according to Nymox Pharmaceutical Corporation.

The drug candidate has been extensively tested in animal models of cell loss where it has been safely tolerated and has been shown to significantly limit the damage. according to a company spokesperson.

"One of the key advantages of our candidate appears to be its safety profile," said Dr. Michael Munzar, Medical Director at Nymox. "Thus far there has been no evidence whatsoever of harmful side effects. NXD 9062 has exciting potential for this devastating disease."

Nymox hopes to begin testing the drug on humans later in 2002.

Other sources: Nymox Pharmaceutical